TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 2nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 3nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 3nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 3.70nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 4nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Rattus norvegicus (rat))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 4nMT: 2°CAssay Description:The assay was performed as described below, using HEK293 cells transfected with rat TRPV1 (rTRPV1/HEK293). These cells had a geneticin selection mark...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 4nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 5nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 5.30nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 5.40nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 5.90nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 6nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 6.80nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 8.90nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 9.5nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 10nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Rattus norvegicus (rat))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 10nMT: 2°CAssay Description:The assay was performed as described below, using HEK293 cells transfected with rat TRPV1 (rTRPV1/HEK293). These cells had a geneticin selection mark...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 10nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 10nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 10nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 10nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 10nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 10nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 10nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 10nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 10nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 10nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 10nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 10nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 10nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 10nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 10nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 10nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 10nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 10nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Rattus norvegicus (rat))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 10nMT: 2°CAssay Description:The assay was performed as described below, using HEK293 cells transfected with rat TRPV1 (rTRPV1/HEK293). These cells had a geneticin selection mark...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Rattus norvegicus (rat))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 10nMT: 2°CAssay Description:The assay was performed as described below, using HEK293 cells transfected with rat TRPV1 (rTRPV1/HEK293). These cells had a geneticin selection mark...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 10nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 10nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Rattus norvegicus (rat))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 10nMT: 2°CAssay Description:The assay was performed as described below, using HEK293 cells transfected with rat TRPV1 (rTRPV1/HEK293). These cells had a geneticin selection mark...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Rattus norvegicus (rat))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 10nMT: 2°CAssay Description:The assay was performed as described below, using HEK293 cells transfected with rat TRPV1 (rTRPV1/HEK293). These cells had a geneticin selection mark...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Rattus norvegicus (rat))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 10nMT: 2°CAssay Description:The assay was performed as described below, using HEK293 cells transfected with rat TRPV1 (rTRPV1/HEK293). These cells had a geneticin selection mark...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Rattus norvegicus (rat))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 10nMT: 2°CAssay Description:The assay was performed as described below, using HEK293 cells transfected with rat TRPV1 (rTRPV1/HEK293). These cells had a geneticin selection mark...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Rattus norvegicus (rat))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 10nMT: 2°CAssay Description:The assay was performed as described below, using HEK293 cells transfected with rat TRPV1 (rTRPV1/HEK293). These cells had a geneticin selection mark...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Rattus norvegicus (rat))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 10nMT: 2°CAssay Description:The assay was performed as described below, using HEK293 cells transfected with rat TRPV1 (rTRPV1/HEK293). These cells had a geneticin selection mark...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 10nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Rattus norvegicus (rat))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 13nMT: 2°CAssay Description:The assay was performed as described below, using HEK293 cells transfected with rat TRPV1 (rTRPV1/HEK293). These cells had a geneticin selection mark...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 16nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 18nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 18nMT: 2°CAssay Description:HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRP...More data for this Ligand-Target Pair